scholarly journals Patient‐reported symptoms and experience following Guillain‐Barré syndrome and related conditions: Questionnaire development and validation

2021 ◽  
Author(s):  
Aloysius Niroshan Siriwardena ◽  
Joseph N. A. Akanuwe ◽  
Vanessa Botan ◽  
Despina Laparidou ◽  
Ffion Curtis ◽  
...  
Keyword(s):  
Questionnaire Development ◽  
Guillain Barre Syndrome ◽  
Patient Reported ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Development And Validation ◽  
Questionnaire Development And Validation

scholarly journals A case of guillain-barré syndrome associated with post-covid infection during 2nd wave of coronavirus in india

2021 ◽  
pp. 342-344
Author(s):  
Anil Kumar Behera ◽  
Syed Naqueeb ul Hassan ◽  
Chaitanya Challa ◽  
K Divya Madhusudhan Reddy ◽  
V Bharat R Bhardwaj ◽  
...  
Keyword(s):  
Axonal Neuropathy ◽  
Inflammatory Cells ◽  
Multiple Organ ◽  
Guillain Barre Syndrome ◽  
Polymerase Chain Reaction Test ◽  
Immune Mediated ◽  
Organ Systems ◽  
Patient Reported ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

The novel coronavirus-COVID-19 was detected in Wuhan city of Hubei Province in China on December 31, 2019. Coronaviruses are known to infect multiple organ systems, with respiratory complications being the most obvious symptoms. Although, neurological manifestations are quite rarely reported in cases of COVID-19. In this report, we present the case of a 57-year-old male patient reported with complaints of acute progressive symmetric quadriparesis and recently recovered from COVID-19. Two weeks prior to hospitalization, the patient suffered from cough and fever. The reverse transcriptase-polymerase chain reaction test for COVID-19 infection was positive. Electrodiagnostic tests showed that the patient had acute motor and sensory axonal neuropathy variant of Guillain-Barré Syndrome (GBS). COVID-19 virus stimulates the inflammatory cells and as a result, creates immune-mediated processes. GBS is an immune-mediated disorder. It is not clear whether COVID-19 infection induces the production of antibodies against specific gangliosides. Further investigations should be conducted in regards to the mechanism of GBS in patients with COVID-19 in the future.

scholarly journals Guillain Barré Syndrome as Primary Presentation of Systemic Lupus Erythematosus (SLE-GBS) in a Teenage Girl: A Case Report

2021 ◽  
Author(s):  
Elham Beshir ◽  
Ernestina Belt ◽  
Nidheesh Chencheri ◽  
Aqdas Ismail ◽  
Marco Pallavidino ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Oral Prednisolone ◽  
Guillain Barre Syndrome ◽  
Initial Assessment ◽  
Patient Reported ◽  
Guillain Barré Syndrome ◽  
Neuropsychiatric Manifestations ◽  
Guillain Barré ◽  
Pediatric Sle

Abstract Background: Peripheral nervous system (PNS) involvement, including Guillain Barré Syndrome (GBS), accounts for fewer than 10% of SLE cases with neuropsychiatric manifestations. GBS as the presenting, major manifestation of pediatric SLE is extremely rare, and the best treatment approach is unknown. Case presentation: A 14-year-old, previously healthy female Emirati teenager presented with a classic picture of GBS with ascending, progressive bilateral muscle weakness leading to respiratory insufficiency within five weeks of symptom onset, associated with typical protein-cell dissociation in cerebro-spinal fluid and nerve root enhancement demonstrated by spinal MRI. Subsequently, elevated anti-dsDNA and anti-Smith/RNP and anti-SS-A and -B antibody concentrations were detected in serum, suggestive of SLE. GBS treatment was initiated with IVIG and methylprednisolone pulses, with minimal improvement. The patient required endotracheal intubation and ventilation, followed by a second course of IVIG, rituximab, and eventually plasma exchange (PLEX) therapy. The diagnosis of lupus-associated GBS was corroborated by a kidney biopsy demonstrating lupus nephritis WHO class II with “full house” immunofluorescence pattern. After 14 PLEX sessions, her muscle strength and respiratory efforts had improved substantially. Treatment was completed with two more rituximab infusions, followed by mycophenolate mofetil, in addition to HCQ and tapering doses of oral prednisolone. Five weeks after the last PLEX treatment, she had regained her usual strength and achieved full, sustained recovery from GBS. While she continued to demonstrate moderate anti-dsDNA antibodies and high-level anti-Smith and Sjogren antibodies, C3, C4 and urine readings quickly normalized with no other manifestations of lupus or lupus nephritis 11 months after the initial assessment. At this time she was maintained with hydroxychloroquine, with ongoing depletion of circulating B cells. To our knowledge, this is only the third pediatric patient reported with SLE-GBS.Conclusions: We report severe GBS as the first, dominant manifestation of pediatric SLE. Our case and a review of the literature reveal that cconventional GBS therapy may not be adequate to treat this rare lupus presentation. SLE should be included in the differential diagnosis of GBS. Importantly, treatment experiences and outcomes of such cases need be reported to inform future treatment recommendations.

Sign in / Sign up

Export Citation Format

Share Document